why choose us

First received: April 18, 2023

Clinical Trial: A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed/ Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma

Brief Summary: This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.

Read more